Hanall Biopharma (009420) — Long-term Investment Intensity
Hanall Biopharma (009420) has a Long-term Investment Intensity of 9.4% as of December 2019. Long-term investments of ₩17.93 Billion represent 9.4% of total assets of ₩191.38 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Hanall Biopharma asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Hanall Biopharma Long-term Investment Intensity (2013–2019)
This chart shows how Hanall Biopharma's Long-term Investment Intensity has evolved across 7 annual periods from 2013 to 2019. As of December 2019, the intensity stands at 9.4%, reflecting long-term investments of ₩17.93 Billion against total assets of ₩191.38 Billion KRW. For the complete balance sheet picture, see 009420 total assets.
Annual Long-term Investment Intensity for Hanall Biopharma (2013–2019)
The table below presents the year-by-year Long-term Investment Intensity for Hanall Biopharma from 2013 to 2019, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read Hanall Biopharma (009420) total liabilities for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (KRW) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 9.4% | ₩17.93 Billion | ₩191.38 Billion | ▲ +5.6 pp |
| 2018 | 3.8% | ₩6.14 Billion | ₩162.30 Billion | ▲ +2.7 pp |
| 2017 | 1.0% | ₩1.76 Billion | ₩168.70 Billion | ▼ -0.4 pp |
| 2016 | 1.4% | ₩1.78 Billion | ₩124.73 Billion | ▲ +0.5 pp |
| 2015 | 0.9% | ₩1.06 Billion | ₩117.13 Billion | ▲ +0.6 pp |
| 2014 | 0.3% | ₩264.91 Million | ₩87.17 Billion | ▼ -0.5 pp |
| 2013 | 0.8% | ₩805.28 Million | ₩97.85 Billion | — |